Friedman Alan W
Medical Clinic of Houston, 1707 Sunset Boulevard, Houston, TX 77005, USA.
J Clin Rheumatol. 2006 Apr;12(2):70-7. doi: 10.1097/01.rhu.0000208612.33819.8c.
Osteoporosis is a systemic skeletal disorder characterized by compromised bone strength that predisposes individuals to increased fracture risk. Bone strength is determined by its material and structural properties. Bone mineral density (BMD) is a useful tool for diagnosis; however, this parameter provides information regarding only the quantity of mineral in bone, which is only one component of bone strength. Osteoporosis treatments have been shown to have beneficial effects on bone turnover, microarchitecture, and/or mineralization, all of which can help account for the reductions in fracture risk above and beyond changes in BMD. Newer noninvasive imaging methods are being developed that assess bone strength independent of BMD, and these methods should improve the assessment of fracture risk and response to treatment. These imaging methods are not currently available for routine clinical use, and therefore, clinicians need to continue for now to rely on surrogate markers of bone fragility, including BMD, prevalent fracture, and other important risk factors for fracture.
骨质疏松症是一种全身性骨骼疾病,其特征是骨强度受损,使个体骨折风险增加。骨强度由其材料和结构特性决定。骨密度(BMD)是一种有用的诊断工具;然而,该参数仅提供有关骨中矿物质数量的信息,而这只是骨强度的一个组成部分。已证明骨质疏松症治疗对骨转换、微结构和/或矿化具有有益作用,所有这些都有助于解释骨折风险的降低,这种降低超出了骨密度变化的范围。正在开发更新的非侵入性成像方法,这些方法可独立于骨密度评估骨强度,并且这些方法应能改善对骨折风险和治疗反应的评估。目前这些成像方法尚不能用于常规临床应用,因此,临床医生目前仍需依靠骨脆性的替代指标,包括骨密度、既往骨折情况以及其他重要的骨折风险因素。